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200 
-----
Identify a Plurality of Cell Donors 
Who Are Determined to Have a ~ Disease State or Susceptibility to 
Disease State 205 
Harvest Cells from Identified Cell 
---
210 
Donors 
Subject Harvested Cells from 
----
215 
Identified Donors to a 
Dcdiffcrcntiating Agent 
Expand Dedifferentiated Cells 
-
225 
Store Cells in Separate Containers 
Under Conditions to Keep Viable - 230 
Obtain Predetermined 235 
Characteristic(s) Information from -
Cells, and optionally input 
information into database computer FIG.2 
unit 
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300 
----
Receive Request for Tnfonnation 
about Stem Cells in Stem Cell Bank 305 
Display Information about Stem 
Cells in Stem Cell Bank in 
------
310 
Response to Request by User 
Receive Request Regarding 
-- 315 Information about a Selected Stem 
---------
Cell 
---------
Display Tnfonnation about Selected 
Stem Cell i-- 325 
Receive Request to Purchase 
Selected Stem Cell 
-
330 
Display Confirmation of Purchased 
Stem Cells 
-
335 
Ship Purchased Stem Cells FIG. 3 
-
340 
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1 2 
STEM CELL BANKING SYSTEM 
BACKGROUND 
Much research is being conducted to study stem cells and 
to devise ways of utilizing stem cells in treating various 
neurological diseases and injuries, as well as diseases and 
injuries of other organ systems. It is generally recognized that 
stem cell technologies hold tremendous promise for treating 
and ultimately curing neurologically related diseases, injuries 
or dysfunctions and those of other organ systems. However, 
despite the interest in stem cell research, scientists do not have 
a systematic system for obtaining stem cells for research 
purposes. 
database computer comprising at least one processing mod-
ule, a display, and a storage medium comprising information 
of at least one characteristic for each of said stem cell popu-
lation; and at least one program code module for causing said 
information to be viewable on said display upon command by 
a user. In a specific embodiment, the invention pertains to a 
stem cell banking system wherein the stem cell populations 
comprise stem cells obtained from subjects who have a dis-
ease condition. The disease condition may include, but is not 
10 limited to, cardiovascular disease, cancer, neurological dis-
ease, such as Alzheimer's disease, Parkinson's disease, Hun-
tington's Chorea, Lou-Gherig's disease, etc. Stem cells are 
harvested from different subjects having a different disease, 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows a diagram of a stem cell banking system 
embodiment. 
15 and the stem cells are characterized. The characteristic(s) 
is/are inputted into the database computer. In addition, or 
alternatively, cells are characterized based on a specific phe-
notype not necessarily associated with a disease condition. 
For example, not to be construed as limiting, liver cells can be 
FIG. 2 shows a flow diagram of a method embodiment for 
producing a stem cell bank. 
FIG. 3 shows a flow diagram of a method embodiment for 
providing for purchase of stem cell samples. 
20 characterized based on their ability to metabolized certain 
compounds such as caffeine, alcohol, drug agents, etc. to 
study genetic bases of such different metabolism abilities, or 
underlying physiology associated therewith. Other types of 
cells can be characterized based on functional and/or mor-
DETAILED DESCRIPTION 25 phological phenotypes. 
The subject invention is based on the inventors' realization 
that there is a need for a convenient systematic access to 
different stem cell lines. The inventors have realized that the 
ability to identify stem cell lines derived from somatic cells 30 
harvested from healthy subjects and subjects having known 
disease states or disease symptoms would be invaluable to 
researchers. Subjects may be human or nonhuman verte-
brates. The inventors have developed methods of harvesting 
somatic cells, processing cells to increase their potency and 35 
cataloguing cells according to specific characteristics and 
traits. 
Examples, include, but are not limited to, mesenchymal 
stem cells (MeSCs ), neural stem cells (NSCs ), hematopoietic 
stem cells (HSCs ), fibroblasts or endothelial cells. Population 
of stem cells can be derived from a number of different 
sources. Stem populations useful in conjunction with certain 
embodiments described herein include, but are not limited to, 
brain-derived neural stem cells, bone marrow derived mesen-
chymal stem cells, adipose-derived mesenchymal stem cells, 
blood-derived hematopoietic stem cells, cord-blood-derived 
stem cells. 
In certain embodiments, the harvested cells may be sub-
jected to conditions to influence differentiation or dedifferen-
tiation through introduction of engineered vectors, or other 
For example, according to another embodiment, cells are 
harvested, catalogued according to predetermined character-
istics, e.g., phenotypic information, morphological character-
istics, differentiation profile, blood type, major histocompat-
ibility complex, disease state of donor, or genotypic 
information (e.g. single nucleated polymorphisms, 'SNPs' of 
a specific nucleic acid sequence associated with a gene, or 
genomic or mitochondrial DNA), and stored under appropri-
40 genetic material. Dedifferentiation comprises the manipula-
tion of a cell such that it takes on the properties of a less 
differentiated cell. U.S. application Ser. Nos. 11/258,401; 
11/258,603; 11/258,392 and 11/258,360 discuss various 
methods for biasing potency and/or differentiation of stem 
45 cells, and are incorporated herein by reference. 
In a specific example, adult somatic cells including but not 
limited to white blood cells, fibroblasts, mesenchymal stem 
cells, and skin cells can be treated with nucleotide derivatives 
such as BrdU or 5-azacytidine to epigenetically modify the 
50 cells to increase their developmental potential. Additionally, 
cells can be treated with genes that expand the potency of cells 
including but not limited to genes that are responsible for 
maintaining the properties of embryonic stem cells such as 
ate conditions (typically by freezing) to keep the stem cells 
alive and functioning. Cataloguing may constitute creating a 
centralized record of the characteristics obtained for each cell 
population, such as, but not limited to, an assembled written 
record or a computer database with information inputted 
therein. Essentially, this embodiment pertains to the produc-
tion of a stem cell bank. The stem cell bank facilitates the 
selection from a plurality of samples of a specific stem cell 
sample suitable for a researcher's needs. Thus, another 
embodiment of the subject invention pertains to a stem cell 55 
bank comprising a plurality of stem cells samples obtained 
from separate sources and which are characterized and cata-
logued according to at least one predetermined characteristic. 
An additional embodiment pertains to a method of establish-
ing a stem cell bank comprising collecting stem samples from 60 
multiple sources; cataloguing the samples according to at 
least one predetermined characteristic and storing the cells 
under conditions that keep cells viable. 
According to a specific embodiment, the subject invention 
pertains to a stem cell banking system comprising a plurality 65 
of stem cell populations disposed in individual containers 
under conditions to keep said stem cell populations viable; a 
nanog. 
Cells can be positively selected for using cell-specific 
markers including but not limited to CD34, CD133 (hemato-
poietic stem cells), STR0-1, SH2, SH3, (mesenchymal stem 
cells), nestin, PSA-NCAM (neural stem cells). Cells can also 
be purified through negative selection by selecting out cells 
that express markers not present in the desired cell popula-
tion. For example, lineage markers indicating differentiation 
such as CD38, CD45, and "Lin" markers (blood cell lineage 
proteins expressed in differentiating blood cells) can select 
out white blood cells from a mixture of cells. 
Cells can also be selected using physical properties such as 
growth characteristics, adhesion, and/or density. For 
example, a density gradient can separate red blood cells from 
US 8,759,090 B2 
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a solution of bone marrow and adhesion of cells to a culture 
flask can select for mesenchymal cells (while hematopoietic 
cells remain non-adherent). 
As discussed above, stem cells may be procured using 
convention techniques in the stem cell art. In one example, 5 
stem cells are obtained from bone marrow or blood. See, for 
example, Friedenstein A J, Gorskaja J F, Kulagina N N, Exp 
Hematol. 1976 September; 4(5):267-74; and Caplan A I J, 
Orthop Res. 1991 September; 9(5):641-50. A bone marrow 
sample is explanted from a donor and hematopoietic stem 10 
cells are isolated from the marrow sample according to 
known techniques, including use flow cytometry or an affinity 
column. See, for example, U.S. Patent Publication Nos. 
20040265996; 20050158857; 20060088890; and 
20060073124. In a specific embodiment, hematopoietic cells 15 
are isolated using positive or negative selection. See U.S. 
Patent Publication No. 20060073124. Negative selection 
removes unwanted cells using certain markers such as C45 or 
positive selection using CD34. 
Once cells are isolated they may be cultured, expanded, 20 
subjected to external biasing factors and/or genetically modi-
fied by introduction of genes encoding for biasing factors, see 
U.S. application Ser. Nos 11/258,401; 11/258,603; 11/258, 
392 and 11/258,360 are incorporated herein by reference. 
Mesenchymal cells may be isolated by similar techniques or 25 
through the use of a gradient, such as FI COL gradient. Mes-
enchymal cells in a bone marrow sample will attach to sur-
face, whereas other undesired cells will not attach and remain 
in the media. The media with the undesired cells is removed 
leaving the desired mesenchymal cells. The mesenchymal 30 
cells, as with other cells, are cultured, expanded, subjected to 
external biasing factors and/or genetically modified. 
In the context of the present application, a polynucleotide 
sequence is "homologous" with the sequence according to the 
invention if at least 70%, preferably at least 80%, most pref- 35 
erably at least 90% of its base composition and base sequence 
corresponds to the sequence according to the invention. 
According to the invention, a "homologous protein" is to be 
understood to comprise proteins which contain an amino acid 
sequence at least 70% of which, preferably at least 80% of 40 
which, most preferably at least 90% of which, corresponds to 
a given amino acid sequence; wherein corresponds is to be 
understood to mean that the corresponding amino acids are 
either identical or are mutually homologous amino acids. The 
expression "homologous amino acids" denotes those which 45 
have corresponding properties, particularly with regard to 
their charge, hydrophobic character, steric properties, etc. 
Thus, in one embodiment the protein may be from 70% up to 
less than 100% homologous to nanog (SEQ ID NO. 2). 
Homology, sequence similarity or sequence identity of 50 
nucleotide or amino acid sequences may be determined con-
ventionally by using known software or computer programs 
such as the BestFit or Gap pairwise comparison programs 
(GCG Wisconsin Package, Genetics Computer Group, 575 
Science Drive, Madison, Wis. 53711). BestFit uses the local 55 
homology algorithm of Smith and Waterman, Advances in 
Applied Mathematics 2: 482-489 (1981), to find the best 
segment of identity or similarity between two sequences. Gap 
performs global alignments: all of one sequence with all of 
another similar sequence using the method of Needleman and 60 
Wunsch, J. Mo!. Biol. 48:443-453 (1970). When using a 
sequence alignment program such as BestFit, to determine 
the degree of sequence homology, similarity or identity, the 
default setting may be used, or an appropriate scoring matrix 
may be selected to optimize identity, similarity or homology 65 
scores. Similarly, when using a program such as BestFit to 
determine sequence identity, similarity or homology between 
4 
two different amino acid sequences, the default settings may 
be used, or an appropriate scoring matrix, such as blosum45 
or blosum80, may be selected to optimize identity, similarity 
or homology scores. 
The term "isolated" means separated from its natural envi-
ronment. 
The term "polynucleotide" refers in general to polyribo-
nucleotides and polydeoxyribonucleotides, and can denote an 
unmodified RNA or DNA or a modified RNA or DNA. 
The term "polypeptides" is to be understood to mean pep-
tides or proteins which contain two or more amino acids 
which are bound via peptide bonds. 
The polypeptides for use in accord with the teachings 
herein include polypeptides corresponding to nanog, and also 
includes those, at least 70% of which, preferably at least 80% 
of which, are homologous with the polypeptide correspond-
ing to nanog, and most preferably those which exhibit a 
homology of least 90% to 95% with the polypeptide corre-
sponding to nanog and which have dedifferentiating influ-
ence. Thus, the polypeptides may have a homology of from 
70% to up to 100% with respect to SEQ ID NO. 2. 
As used herein, a "polypeptide sequence exhibiting dedif-
ferentiating influence" is a polypeptide whose presence in the 
cell causes an increase in potency, or transformation from a 
less developmentally potent cell to a more developmentally 
potent cell. Examples of such polypeptide sequences include 
the expression products of SEQ ID NO. 1, and polynucleotide 
sequences that hybridize to the complement of SEQ ID NO. 1, 
as well as expression products of the polynucleotide 
sequences listed in Table 1: 
Table 1 
Pem (mouse GI: 1255173) 
Fan Y, et al. Developmental Biology 210: 481-496. 1999 
POU5Fl (Unigene Hs.2860) 
Sox2 (Unigene Hs.816) 
HESXl (Unigene Hs.171980) 
UTFl (Unigene Hs.158307) 
REX! (Unigene Hs.335787) 
FOXD3 (Unigene Hs.120204) 
GBX2 (Unigene Hs.326290) 
NANOG (Unigene Hs.326290) 
LIN-28 (Unigene 86154) 
TGIF 
DNMT3A/B (251673) 
TGFFl (75561) 
Richards M, et al. Stem Cells 22: 51-64. 2004 
EGS-1 (accession# X57708.1) 
FGF4 Tanaka T, et al. Genone Research 12: 1921-1928. 
2002. 
Rex-1 (accession# AF 4 5 0 4 5 4) 
The terms "stringent conditions" or "stringent hybridiza-
tion conditions" includes reference to conditions under which 
a polynucleotide will hybridize to its target sequence, to a 
detectably greater degree than other sequences (e.g., at least 
2-fold over background). Stringent conditions are sequence-
dependent and will be different in different circumstances. By 
controlling the stringency of the hybridization and/or wash-
ing conditions, target sequences can be identified which are 
100% complementary to the probe (homologous probing). 
Alternatively, stringency conditions can be adjusted to allow 
some mismatching in sequences so that lower degrees of 
similarity are detected (heterologous probing). 
Typically, stringent conditions will be those in which the 
salt concentration is less than about 1.5 M Na ion, typically 
about 0.01 to 1.0 MNa ion concentration ( orother salts) at pH 
7 .0 to 8.3 and the temperature is at least about 30° C. for short 
probes (e.g., !Oto 50 nucleotides) andat least about 60° C. for 
US 8,759,090 B2 
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long probes (e.g., greater than 50 nucleotides). Stringent con-
ditions may also be achieved with the addition of destabiliz-
ing agents such as formamide. Exemplary low stringency 
conditions include hybridization with a buffer solution of30 
to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl 
sulphate) at 37° C., anda wash in lx to 2xSSC (20xSSC=3.0 
6 
M NaCl/0.3 M trisodium citrate) at 50 to 55° C. Exemplary 
moderate stringency conditions include hybridization in 40 to 
45%formamide, 1MNaCl,1%SDSat37°C.,andawashin 
0.5x to lxSSC at 55 to 60° C. Exemplary high stringency 10 
conditions include hybridization in 50% formamide, 1 M 
NaCl, 1 % SDS at 37° C., and a washinO.lxSSC at 60 to 65° 
endogenous polynucleotide sequence that has been activated. 
Nanog expression may be activated by the provision of Oct 4 
and/or Sox2, which typically form a dimer. In a specific 
embodiment, the cellular component is a nucleus, liposome, 
or mitochondria. Such endogenous polynucleotide sequence 
or cellular component contacted by nanog or nanog may be 
removed from a cell or cellular component and introduced 
into another cell or cellular component. 
Example 1 
Stem Cell Bank System Embodiment 
C. 
Specificity is typically the function of post-hybridization 
washes, the critical factors being the ionic strength and tem-
perature of the final wash solution. For DNA-DNA hybrids, 
the Tm can be approximated from the equation of Meinkoth 
and Wahl, Anal. Biochem., 138:267-284 (1984): Tm=81.5° 
C.+16.6 (log M)+0.41 (% GC)-0.61 (% form)-500/L; where 
M is the molarity of monovalent cations, % GC is the per-
centage of guano sine and cytosine nucleotides in the DNA, % 
form is the percentage of formamide in the hybridization 
solution, and Lis the length of the hybrid in base pairs. The 
Tm is the temperature (under defined ionic strength and pH) 
at which 50% of a complementary target sequence hybridizes 
to a perfectly matched probe. Tm is reduced by about 1° C. for 
each 1 % of mismatching; thus, Tm, hybridization and/or 
wash conditions can be adjusted to hybridize to sequences of 
the desired identity. For example, if sequences with approxi-
mately 90% identity are sought, the Tm can be decreased 10° 
C. Generally, stringent conditions are selected to be about 5° 
C. lower than the thermal melting point (Tm) for the specific 
sequence and its complement at a defined ionic strength and 
pH. However, severely stringent conditions can utilize a 
hybridization and/or wash at 1, 2, 3, or 4 ° C. lower than the 
thermal melting point (Tm); moderately stringent conditions 
can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10° C. 
lower than the thermal melting point (Tm); low stringency 
conditions can utilize a hybridization and/or wash at 11, 12, 
In one embodiment, as shown in FIG. 1, the subject inven-
15 tion relates to a stem cell banking system embodiment 100 
comprising a stem cell bank 105. A plurality of stem cell 
populations are processed, such as by the method discussed in 
FIG. 2. In a specific embodiment, the stem cell populations 
102 are stored in a housing facility 101 comprising the suit-
20 able freezing systems to maintain stem cells in a viable con-
dition. Freezing systems may include but are not limited to a 
conventional freezer or a chamber holding a freezing medium 
such as liquid nitrogen, dry ice, frozen water, etc. The stem 
cell bank 105 maintains a stem cell database computer unit 
25 107. Users 112, 114, 116 each having user computer units 
113, 115, 117 that interface with database computer unit 107 
via a network connection 109. Each computer unit comprises 
at least one processing module 120, 121, 122, and 123, 
respectively, for processing information. Furthermore, each 
30 computer unit is communicatingly connected to a display 
130, 131, 132, and 133. Information directed to stem cell 
populations 102 are stored on database computer 107 which 
are conveyed to users 112, 114, 116 on user computer units 
113, 115, and 117 via network connection, such as according 
35 to FIG. 3 as described in further detail below. The system 
provides the customer the ability to evaluate stem cell popu-
lations to determine which are suitable for their ongoing 
research and facilitates the transaction of purchasing stem 
cells and proper shipment. 
As will be appreciated by one of skill in the art, embodi-
ments of the present invention may be embodied as a device 
or system comprising a processing module, and/or computer 
program product comprising at least one program code mod-
ule. Accordingly, the present invention may take the form of 
13, 14, 15, or 20° C. lower than the thermal melting point 40 
(Tm). Using the equation, hybridization and wash composi-
tions, and desired Tm, those of ordinary skill will understand 
that variations in the stringency of hybridization and/or wash 
solutions are inherently described. If the desired degree of 
mismatching results in a Tm of less than 45° C. (aqueous 
solution) or 32° C. (formamide solution) it is preferred to 
increase the SSC concentration so that a higher temperature 
can be used. An extensive guide to the hybridization of 
nucleic acids is found in Current Protocols in Molecular 
Biology, Chapter 2, Ausubel, et al., Eds., Greene Publishing 
and Wiley-Interscience, New York (2000). 
45 an entirely hardware embodiment or an embodiment combin-
ing software and hardware aspects. Furthermore, the present 
invention may include a computer program product on a 
computer-usable storage medium having computer-usable 
program code means embodied in the medium. Any suitable 
50 computer readable medium may be utilized including hard 
disks, CD-ROMs, DVDs, optical storage devices, or mag-
netic storage devices. Accordingly, polynucleotide sequences that hybridize to 
the complement of the sequence in SEQ ID NO. 1 are con-
templated for use in dedifferentiating cells as taught herein. 
According to another embodiment, the subject invention 
comprises a method of influencing transcription of an endog-
enous polynucleotide sequence comprising contacting a non-
embryonic cell or cellular component comprising an endog-
enous polynucleotide sequence with a nanog protein or 
protein encoded by a polynucleotide sequence that hybridizes 
to a complement of SEQ ID NO. 1 under stringent conditions 
(i.e. nanog-like protein). Such influence may further include, 
but is not limited to, demethylation of DNA and reversal 
histone acetylation. The nanog protein or nanog-like protein 
may be one expressed by a polynucleotide sequence intro-
duced in the cell or cellular component, or protein delivered 
into the cell or cellular component, or protein expressed by an 
The term "processing module" may include a single pro-
cessing device or a plurality of processing devices. Such a 
55 processing device may be a microprocessor, micro-control-
ler, digital signal processor, microcomputer, central process-
ing unit, field programmable gate array, progranimable logic 
device, state machine, logic circuitry, analog circuitry, digital 
circuitry, and/or any device that manipulates signals (analog 
60 and/or digital) based on operational instructions. The pro-
cessing module may have operationally coupled thereto, or 
integrated therewith, a memory device. The memory device 
may be a single memory device or a plurality of memory 
devices. Such a memory device may be a read-only memory, 
65 random access memory, volatile memory, non-volatile 
memory, static memory, dynamic memory, flash memory, 
and/or any device that stores digital information. A computer, 
US 8,759,090 B2 
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as used herein, is a device that comprises at least one process-
ing module, and optionally at least one memory device. 
The computer-usable or computer-readable medium may 
be or include, for example, but not limited to, an electronic, 
magnetic, optical, electromagnetic, infrared, or semiconduc-
tor system, apparatus, device, or propagation medium. More 
specific examples (a non-exhaustive list) of the computer-
readable medium would include the following: an electrical 
connection having one or more wires, a portable computer 
diskette, a random access memory (RAM), a read-only 10 
memory (ROM), an erasable progranmiable read-only 
memory (EPROM or Flash memory), an optical fiber, and a 
portable compact disc read-only memory (CD-ROM), a CD 
ROM, a DVD (digital video disk), or other electronic storage 
medium. Note that the computer-usable or computer-read- 15 
able medium could even be paper or another suitable medium 
upon which the program is printed, as the program can be 
electronically captured, via, for instance, optical scarming of 
the paper or other medium, then compiled, interpreted or 
otherwise processed in a suitable marmer if necessary, and 20 
then stored in a computer memory. 
Computer program code for carrying out operations of 
certain embodiments of the present invention may be written 
in an object oriented and/or conventional procedural pro-
gramming languages including, but not limited to, Java, 25 
Smalltalk, Perl, Python, Ruby, Lisp, PHP, "C", FORTRAN, 
or C++. The program code may execute entirely on the user's 
computer, partly on the user's computer, as a stand-alone 
software package, partly on the user's computer and partly on 
a remote computer or entirely on the remote computer. In the 30 
latter scenario, the remote computer may be connected to the 
user's computer through a local area network (LAN) or a 
wide area network (WAN), or the connection may be made to 
8 
Example 2 
Harvesting and Processing of Stem Cells 
FIG. 2 illustrates one embodiment 200 of a method for 
harvesting and processing of stem cells for production of a 
stem cell bank. A plurality of cell donors are identified 205. In 
certain embodiments, donors are chosen due to the presence 
of a certain genetic profile and/or disease condition. Cells are 
harvested from individual donors 210. Numerous cell types 
may be suitable for harvesting including, including, but not 
limited to the cells types described above. Harvested stem 
cells are dedifferentiated 215. This may be achieved by a 
number of different methods as discussed above. Dedifferen-
tiated stem cells are expanded 225 and then stored under 
conditions to keep them viable 230. Cells at any of steps 210, 
215, 225, or 230 are studied to obtain information concerning 
predetermined characteristics, and such information is 
optionally inputted into a database computer unit, such as that 
described in FIG. 1. 
FIG. 3 describes a method embodiment 300 for providing 
information about cells at a stem cell bank, such information 
being previously inputted into a database computer unit and 
made available to users on a network, and to provide for 
purchase of stem cells. A request is received from a user to 
obtain information about stem cells 305, such as a request to 
determine availability of a stem cell sample correlating to 
certain keywords, and information is displayed to user regard-
ing one or more stem cells 310, such as stem cells most 
closely matching keyword criteria. Providing an indication 
that no stem cells match the keyword criteria is also contem-
plated in an alternate embodiment. Furthermore, optionally, 
upon listing one or more stem cells most closely matching 
keyword criteria, a request for more detailed information an external computer (for example, through the Internet using 
an Internet Service Provider). 
Certain embodiments of the present invention are 
described herein with reference to flowchart illustrations and/ 
35 about specific selected stem cell population(s) is received 315 
and more detailed information concerning such selected 
population(s) is displayed to user. A request from User to 
purchase selected stem cells is received 330 and a confirma-or block diagrams of methods, apparatus (systems) and com-
puter program products according to embodiments of the 
invention. It will be understood that each block of the flow- 40 
chart illustrations and/or block diagrams, and combinations 
of blocks in the flowchart illustrations and/or block diagrams, 
can be implemented by computer-readable program code 
modules. These program code modules may be provided to a 
processing module of a general purpose computer, special 45 
purpose computer, embedded processor or other program-
mable data processing apparatus to produce a machine, such 
that the program code modules, which execute via the pro-
cessing module of the computer or other programmable data 
processing apparatus, create means for implementing the 50 
functions specified in the flowchart and/or block diagram 
block or blocks. 
These computer program code modules may also be stored 
tion of purchase is sent to the user 335. Purchased stem cells 
may then be shipped to customer and the shipping address 
provided by user 340. 
Example 3 
Methods of Using Identified Stem Cell Populations 
As discussed above, the stem cells of the stem cell bank 
have increased potency which allows for their implementa-
tion in the same types of toxicology studies that are conducted 
with embryonic stem cells. See, for example, U.S. Patent 
Publication Nos. 20020045179 and 20020012905; as well as 
Toxicological Sciences 79, 214-223 (2004) which is itselfand 
the references its cites incorporated herein by way of support 
for various toxicology studies for which the stem cell banking in a computer-readable memory that can direct a computer or 
other programmable data processing apparatus to function in 
a particular manner, such that the program code modules 
stored in the computer-readable memory produce an article of 
manufacture. 
55 system can be used. The following references cited in the 
2004 paper are particularly helpful: 
The computer program code modules may also be loaded 
onto a computer or other programmable data processing 60 
apparatus to cause a series of operational steps to be per-
formed on the computer or other programmable apparatus to 
produce a computer implemented process such that the 
instructions which execute on the computer or other program-
mable apparatus provide steps for implementing the func- 65 
tions specified in the flowchart and/or block diagram block or 
blocks. 
Genschow, E., Scholz, G., Brown, N., Piersma, A., Brady, M., 
Clemann, N., Huuskonen, H., Paillard, F., Bremer, S., 
Becker, K., and Spielmann, H. (2000). Development of 
prediction models for three in vitro embryotoxicity tests in 
an ECVAM validation study. In Vitro Mal. Tax. 13, 51-65. 
Rohwedel, J., Guan, K., Hegert, C., and Wobus,A. M. (2001). 
Embryonic stem cells as an in vitro model for mutagenic-
ity, cytotoxicity and embryotoxicity studies: present state 
and future prospects. Tax. in Vitro 15, 741-753 
Kehat, I., Kenyagin-Karsenti, D., Snir, M., Segev, H., Amit, 
M., Gepstein, A. S., Livne, E., Binah, 0., Itskovitz-Eldor, 
US 8,759,090 B2 
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J., and Gepstein, L. (2001). Human embryonic stem cells 
can differentiate into myocytes with structural and func-
tional properties of cardiomyocytes. J. Clin. Invest. 108, 
407-414. 
Scholz, G., Genschow, E., Pohl, I., Bremer, S., Paparella, M., 
and Raabe, H. (1999). Prevalidation of the embryonic stem 
cell test EST-A new in vitro embryotoxicity test. Toxicol 
In Vitro 13, 675-681. 
While various embodiments of the present invention have 
been shown and described herein, it will be obvious that such 
embodiments are provided by way of example only. Numer-
ous variations, changes and substitutions may be made with-
out departing from the invention herein. Accordingly, it is 
intended that the invention be limited only by the spirit and 
scope of the appended claims. 
Kehat, I., Gepstein, A., Spira, A., Iskovitz-Eldor, J., and Gep-
stein, L. (2002). High-resolution electrophysiological 
assessment of human embryonic stem cell-derived cardi-
omyocytes. Circ. Res. 91, 659-661. 
<160> NUMBER OF SEQ ID NOS, 2 
<210> SEQ ID NO 1 
<211> LENGTH, 1628 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<220> FEATURE, 
<221> NAME/KEY, CDS 
<222> LOCATION, (28) .. (945) 
<400> SEQUENCE, 1 
SEQUENCE LISTING 
U.S. Pat. Nos. 5,993,387; 6,493,724 and 6,640,211 are 
cited to for background information about sample banking 
10 systems. The teachings of all references cited herein are 
incorporated by reference in their entirety to the extent not 
inconsistent with the teachings herein. 
tttttcctcc tcttcctcta tactaac atg agt gtg gat cca get tgt ccc caa 54 
Met Ser Val Asp Pro Ala Cys Pro Gln 
1 5 
age ttg cct tgc ttt gaa gaa tee gac tgt aaa gaa tct tea cct atg 102 
Ser Leu Pro Cys Phe Glu Glu Ser Asp Cys Lys Glu Ser Ser Pro Met 
10 15 20 25 
cct gtg att tgt ggg cct gaa gaa aac tat cca tee ttg caa atg tct 150 
Pro Val Ile Cys Gly Pro Glu Glu Asn Tyr Pro Ser Leu Gln Met Ser 
30 35 40 
tct get gag atg cct cac aca gag act gtc tct cct ctt cct tee tee 198 
Ser Ala Glu Met Pro His Thr Glu Thr Val Ser Pro Leu Pro Ser Ser 
4 5 50 55 
atg gat ctg ctt att cag gac age cct gat tct tee ace agt ccc aaa 246 
Met Asp Leu Leu Ile Gln Asp Ser Pro Asp Ser Ser Thr Ser Pro Lys 
60 65 70 
ggc aaa caa ccc act tct gca gag aat agt gtc gca aaa aag gaa gac 294 
Gly Lys Gln Pro Thr Ser Ala Glu Asn Ser Val Ala Lys Lys Glu Asp 
75 80 85 
aag gtc ccg gtc aag aaa cag aag ace aga act gtg ttc tct tee ace 342 
Lys Val Pro Val Lys Lys Gln Lys Thr Arg Thr Val Phe Ser Ser Thr 
90 95 100 105 
cag ctg tgt gta etc aat gat aga ttt cag aga cag aaa tac etc age 390 
Gln Leu Cys Val Leu Asn Asp Arg Phe Gln Arg Gln Lys Tyr Leu Ser 
110 115 120 
etc cag cag atg caa gaa etc tee aac ate ctg aac etc age tac aaa 438 
Leu Gln Gln Met Gln Glu Leu Ser Asn Ile Leu Asn Leu Ser Tyr Lys 
125 130 135 
cag gtg aag ace tgg ttc cag aac cag aga atg aaa tct aag agg tgg 486 
Gln Val Lys Thr Trp Phe Gln Asn Gln Arg Met Lys Ser Lys Arg Trp 
140 145 150 
cag aaa aac aac tgg ccg aag aat age aat ggt gtg acg cag aag gee 534 
Gln Lys Asn Asn Trp Pro Lys Asn Ser Asn Gly Val Thr Gln Lys Ala 
155 160 165 
tea gca cct ace tac ccc age etc tac tct tee tac cac cag gga tgc 582 
Ser Ala Pro Thr Tyr Pro Ser Leu Tyr Ser Ser Tyr His Gln Gly Cys 
170 175 180 185 
ctg gtg aac ccg act ggg aac ctt cca atg tgg age aac cag ace tgg 630 
Leu Val Asn Pro Thr Gly Asn Leu Pro Met Trp Ser Asn Gln Thr Trp 
US 8,759,090 B2 
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190 195 200 
aac aat tea ace tgg age aac cag ace cag aac ate cag tee tgg age 
Asn Asn Ser Thr Trp Ser Asn Gln Thr Gln Asn Ile Gln Ser Trp Ser 
205 210 215 
aac cac tee tgg aac act cag ace tgg tgc ace caa tee tgg aac aat 
Asn His Ser Trp Asn Thr Gln Thr Trp Cys Thr Gln Ser Trp Asn Asn 
220 225 230 
cag gee tgg aac agt ccc ttc tat aac tgt gga gag gaa tct ctg cag 
Gln Ala Trp Asn Ser Pro Phe Tyr Asn Cys Gly Glu Glu Ser Leu Gln 
235 240 245 
tee tgc atg cac ttc cag cca aat tct cct gee agt gac ttg gag get 
Ser Cys Met His Phe Gln Pro Asn Ser Pro Ala Ser Asp Leu Glu Ala 
250 255 260 265 
gee ttg gaa get get ggg gaa ggc ctt aat gta ata cag cag ace act 
Ala Leu Glu Ala Ala Gly Glu Gly Leu Asn Val Ile Gln Gln Thr Thr 
270 275 280 
agg tat ttt agt act cca caa ace atg gat tta ttc eta aac tac tee 
Arg Tyr Phe Ser Thr Pro Gln Thr Met Asp Leu Phe Leu Asn Tyr Ser 
285 290 295 
atg aac atg caa cct gaa gac gtg tga agatgagtga aactgatatt 
Met Asn Met Gln Pro Glu Asp Val 
300 305 
actcaatttc agtctggaca ctggctgaat ccttcctctc ccctcctccc atccctcata 
ggatttttct tgtttggaaa ccacgtgttc tggtttccat gatgcctatc cagtcaatct 
catggagggt ggagtatggt tggagcctaa tcagcgaggt ttcttttttt ttttttccta 
ttggatcttc ctggagaaaa tacttttttt tttttttttg agacggagtc ttgctctgtc 
gcccaggctg gagtgcagtg gcgcggtctt ggctcactgc aagctccgcc tcccgggttc 
acgccattct cctgcctcag cctcccgagc agctgggact acaggcgccc gccacctcgc 
ccggctaata ttttgtattt ttagtagaga cagggtttca ctgtgttagc caggatggtc 
tcgatctcct gaccttgtga tccgcccgcc tcggcctccc taacagctgg gattacaggc 
gtgagccacc gcgccctgcc tagaaaagac attttaataa ccttggctgc taaggacaac 
attgatagaa gccgtctctg gctatagata agtagatcta atactagttt ggatatcttt 
agggtttaga atctaacctc aagaataaga aatacaagta cgaattggtg atgaagatgt 
att 
<210> SEQ ID NO 2 
<211> LENGTH, 305 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 2 
Met Ser Val Asp Pro Ala Cys Pro Gln Ser Leu Pro Cys Phe Glu Glu 
1 5 10 15 
Ser Asp Cys Lys Glu Ser Ser Pro Met Pro Val Ile Cys Gly Pro Glu 
20 25 30 
Glu Asn Tyr Pro Ser Leu Gln Met Ser Ser Ala Glu Met Pro His Thr 
35 40 45 
Glu Thr Val Ser Pro Leu Pro Ser Ser Met Asp Leu Leu Ile Gln Asp 
50 55 60 
Ser Pro Asp Ser Ser Thr Ser Pro Lys Gly Lys Gln Pro Thr Ser Ala 
65 70 75 80 
Glu Asn Ser Val Ala Lys Lys Glu Asp Lys Val Pro Val Lys Lys Gln 
85 90 95 
12 
678 
726 
774 
822 
870 
918 
965 
1025 
1085 
1145 
1205 
1265 
1325 
1385 
1445 
1505 
1565 
1625 
1628 
US 8,759,090 B2 
13 14 
-continued 
Lys Thr Arg Thr Val Phe Ser Ser Thr Gln Leu Cys Val Leu Asn Asp 
100 105 110 
Arg Phe Gln Arg Gln Lys Tyr Leu Ser Leu Gln Gln Met Gln Glu Leu 
115 120 125 
Ser Asn Ile Leu Asn Leu Ser Tyr Lys Gln Val Lys Thr Trp Phe Gln 
130 135 140 
Asn Gln Arg Met Lys Ser Lys Arg Trp Gln Lys Asn Asn Trp Pro Lys 
145 150 155 160 
Asn Ser Asn Gly Val Thr Gln Lys Ala Ser Ala Pro Thr Tyr Pro Ser 
165 170 175 
Leu Tyr Ser Ser Tyr His Gln Gly Cys Leu Val Asn Pro Thr Gly Asn 
180 185 190 
Leu Pro Met Trp Ser Asn Gln Thr Trp Asn Asn Ser Thr Trp Ser Asn 
195 200 205 
Gln Thr Gln Asn Ile Gln Ser Trp Ser Asn His Ser Trp Asn Thr Gln 
210 215 220 
Thr Trp Cys Thr Gln Ser Trp Asn Asn Gln Ala Trp Asn Ser Pro Phe 
225 230 235 240 
Tyr Asn Cys Gly Glu Glu Ser Leu Gln Ser Cys Met His Phe Gln Pro 
245 250 255 
Asn Ser Pro Ala Ser Asp Leu Glu Ala Ala Leu Glu Ala Ala Gly Glu 
260 265 270 
Gly Leu Asn Val Ile Gln Gln Thr Thr Arg Tyr Phe Ser Thr Pro Gln 
275 280 285 
Thr Met Asp Leu Phe Leu Asn Tyr Ser Met Asn Met Gln Pro Glu Asp 
Val 
305 
290 295 300 
What is claimed is: 
1. A method of producing multiple stem cell populations 40 
for storage in a stem cell bank comprising: 
obtaining mesenchymal stem cells (MeSCs) from a sub-
ject; 
dedifferentiating said MeSCs by introducing into said 
MeSCs an expression cassette that expresses nanog 45 
internally to thereby increase developmental potency of 
said MeSCs; 
expanding said MeSCs; and 
cataloguing said MeSCs according to at least one prede-
termined characteristic; 
wherein said at least one predetermined characteristic com-
prises morphological characteristics, differentiation profile, 
blood type, major histocompatibility complex, disease state 
50 
of donor, or single nucleated polymorphisms a specific 
nucleic acid sequence associated with a gene, or genomic or 55 
mitochondrial DNA. 
2. The method of claim 1, further comprising storing said 
cell populations under conditions to keep said cell popula-
tions viable. 
6. The method of claim 1, wherein said predetermined 
characteristic comprises disease state information of donor. 
7. A stem cell bank comprising: 
stem cell populations produced by the method of claim 1 
and possessed by a single provider, wherein said stem 
cell populations comprise cells having an expression 
cassette comprising a nanog gene; and 
a catalogue comprising information of predetermined 
characteristic information correlating with said stem cell 
populations, wherein said predetermined characteristic 
information comprises morphological characteristics, 
differentiation profile, blood type, major histocompat-
ibility complex, disease state of donor, or single nucle-
ated polymorphisms a specific nucleic acid sequence 
associated with a gene, or genomic or mitochondrial 
DNA. 
8. The stem cell bank of claim 7, wherein said catalogue is 
at least one database computer unit comprising at least one 
processing module and at least one memory device into which 
predetermined characteristic information of said multiple cell 
populations is inputted, and at least one program code module 
3. The method of claim 2, wherein said storing comprises 
placing said cell populations in separate containers under 
freezing conditions. 
60 that causes predetermined characteristic information to be 
displayed onto a display which is in communication with said 
database computer. 
4. The method of claim 1, wherein said cataloguing com-
prises inputting information about said predetermined char-
acteristic of a given cell population into a database computer. 
5. The method of claim 4, wherein said predetermined 
characteristic comprises disease state information of a donor. 
9. The stem cell bank of claim 7, further comprising at least 
one freezer, wherein said cell populations are disposed within 
65 said at least one freezer. 
10. The stem cell bank of claim 9, wherein said at least one 
freezer is in a building. 
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11. The stem cell bank of claim 7, wherein said multiple 
stem cell populations are individually placed within separate 
containers. 
12. A stem cell banking system for storage and making 
available for purchase of stem cell populations comprising: 
at least one freezer; 
multiple stem cell populations produced by the method of 
claim 1 placed within said at least one freezer to produce 
stored stem cell populations, wherein said stem cell 
populations comprise cells having an expression cas- 10 
sette comprising a nanog gene; and 
at least one database computer unit comprising at least one 
processing module and at least one memory device into 
which predetermined characteristic information of said 
multiple cell populations is inputted, and a computer 15 
program product stored on said at least one memory 
device, said computer program product comprising pro-
gram code modules that causes said database computer 
to: 
receive a request for information from a user computer unit 20 
onto a display which is in communication with said 
database about said stored stem populations; 
display information onto said display about stem cells in 
response to said request; 
display field to indicate intent to purchase at least one stem 25 
cell sample; and 
display confirmation of purchase of stem cells upon receiv-
ing a purchase indication. 
* * * * * 
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